Lexaria Bioscience Confirms Nasdaq Listing for Common Stock & Warrants
Ticker: LEXX · Form: 8-K · Filed: Jan 30, 2024
Sentiment: neutral
Topics: regulatory-filing, exchange-listing, corporate-governance
TL;DR
**Lexaria Bioscience's 8-K confirms its common stock and warrants are listed on Nasdaq.**
AI Summary
Lexaria Bioscience Corp. filed an 8-K on January 29, 2024, to report 'Other Events.' This filing confirms the company's registration of its Common Stock and Warrants to Purchase Common Stock under the trading symbols LEXX and LEXXW, respectively, on The Nasdaq Capital Market. This matters to investors because it reaffirms the company's listing status and compliance with exchange requirements, providing transparency about where its securities are traded.
Why It Matters
This filing confirms Lexaria Bioscience's continued listing on The Nasdaq Capital Market, which is crucial for liquidity and investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine disclosure confirming existing listing information and does not introduce new risks.
Analyst Insight
This filing is a standard procedural update. Smart investors would note the confirmed listing on Nasdaq but recognize it doesn't signal new operational changes or financial performance shifts.
Key Numbers
- $0.001 — Par value per share (Par value of Lexaria Bioscience Corp.'s Common Stock)
Key Players & Entities
- Lexaria Bioscience Corp. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where Lexaria's securities are registered
- January 29, 2024 (date) — date of earliest event reported
- LEXX (other) — trading symbol for Common Stock
- LEXXW (other) — trading symbol for Warrants to Purchase Common Stock
- $0.001 (dollar_amount) — par value per share of Common Stock
FAQ
What is the purpose of this 8-K filing by Lexaria Bioscience Corp.?
This 8-K filing, dated January 29, 2024, is categorized under 'Other Events' and serves to report current information, specifically confirming the registration of its Common Stock and Warrants on The Nasdaq Capital Market.
On which exchange are Lexaria Bioscience Corp.'s securities registered?
Lexaria Bioscience Corp.'s Common Stock and Warrants to Purchase Common Stock are registered on The Nasdaq Capital Market, as stated in the filing.
What are the trading symbols for Lexaria Bioscience Corp.'s securities mentioned in the filing?
The trading symbol for Lexaria Bioscience Corp.'s Common Stock is LEXX, and for its Warrants to Purchase Common Stock, the symbol is LEXXW, both listed on The Nasdaq Capital Market.
What is the par value of Lexaria Bioscience Corp.'s Common Stock?
The par value of Lexaria Bioscience Corp.'s Common Stock is $0.001 per share, as indicated in the 'Title of each class' section of the filing.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 29, 2024.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-01-30 13:51:13
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
Filing Documents
- lxrp_8k.htm (8-K) — 22KB
- 0001640334-24-000167.txt ( ) — 142KB
- lxrp-20240129.xsd (EX-101.SCH) — 6KB
- lxrp-20240129_lab.xml (EX-101.LAB) — 14KB
- lxrp-20240129_cal.xml (EX-101.CAL) — 1KB
- lxrp-20240129_pre.xml (EX-101.PRE) — 9KB
- lxrp-20240129_def.xml (EX-101.DEF) — 2KB
- lxrp_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On January 29, 2024, Lexaria Bioscience Corp. ("Lexaria") submitted its Investigational New Drug ("IND") application with the U.S. Food and Drug Administration for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 entitled A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension' . The IND review process, which will take a minimum of 30 days, when successfully concluded will be an important milestone achievement for Lexaria demonstrating that its DehydraTECH technology has met high level formal regulatory scrutiny towards prospective future pharmaceutical commercial registration. Lexaria looks forward to commencing clinical trial HYPER-H23-1 as soon as possible following IND effectiveness, subject to certain conditions including funding. The primary objective of the trial will be to evaluate safety and tolerability in hypertensive patients, and secondary objectives will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: January 30, 2024 3